Risk of Psychosis and Mania With Prescription Amphetamines
This article references data from a large case study conducted between 2005 and 2019, during which there was a five-fold increase in prescription amphetamines within the healthcare system. These findings support the objections raised in my earlier article.
We are often told that a moderate dose of amphetamines – typically considered between 16 mg and 30 mg – is not significant enough to contribute to clinical psychosis or mania. However, doses exceeding 30 mg have been associated with a 5.28-fold increased odds of developing these clinical conditions. Importantly, 82% of psychosis and mania cases were directly linked to high doses of amphetamines.
The research also highlights that doses above 30 mg do not further improve ADHD symptoms and instead negatively impact mental health.
From these findings, I have drawn three key distinctions and insights.
1. Pharmacology Matters
I believe differences in pharmacology are crucial when identifying which symptoms occur, when they occur, and under which medications. Dopamine efflux, in particular, is concerning – especially when incorrect dosing or medication abuse is involved.
While both Ritalin and Adderall increase synaptic dopamine, Adderall causes a four-fold increase in presynaptic dopamine release, which may worsen psychosis. As stated earlier, doses above 30 mg offer no therapeutic benefit.
2. Dosing Should Be More Restrictive
Dosing matters significantly. I believe there should be a dose cap at 15 mg, along with stricter restrictions on amphetamine prescriptions for children and adolescents. In younger populations, dosing errors are more likely and potentially more harmful.
Increased awareness is essential. Medication is powerful and beneficial when used correctly, but it can also be dangerous when misused.
3. Etiological Heterogeneity Must Be Considered
There is strong evidence supporting etiological heterogeneity, a concept I believe is often overlooked in ADHD treatment. While dosing is important, potential synergies with other illnesses are highly likely.
These synergies could be used as early detection mechanisms for clinical psychosis or mania – and potentially even for prevention.
Psychiatry, Amphetamines, and Psychosis Risk
Claim: Psychiatry has been ineffective at generating and implementing novel drugs for psychiatric disorders.
Dr. Taminga supports this claim by citing an American Journal of Psychiatry article showing increased amphetamine use and a corresponding rise in psychosis. Using an intricate analytical system, the study found that psychosis risk significantly increases when patients exceed 30 mg/day.
Moran further explains that doses under 30 mg/day may be used with lower risk, but the loss of insight associated with psychosis can make early detection difficult. Importantly, methylphenidate has shown no evidence of increased psychosis or mania, which may guide future ADHD medication research toward non–dopamine-releasing agents and lower dosages.
This study reinforces the long-standing hypothesis that dopamine – and possibly other amine neurotransmitters – plays a key role in psychosis and mania.
Dr. Taminga further discusses potential etiological factors, including substance use (such as opioids or cannabis), neurodevelopmental deviations during adolescence, and altered cortical excitatory/inhibitory firing in critical brain regions.
She emphasizes that many studies seek a single cause for schizophrenia or bipolar disorder, despite the clear heterogeneity of psychosis and mania. She likens these disorders to a fever – symptoms of multiple underlying conditions rather than a singular disease.
Buprenorphine and Methadone Discontinuation During Pregnancy and Postpartum
A nationwide cohort study published in The American Journal of Psychiatry (December 2025) examined discontinuation rates of methadone vs. buprenorphine during pregnancy and the postpartum period, analyzing over 2,000 unique cases.
Understanding the Medications
Methadone is a full opioid agonist that fully activates opioid receptors to prevent withdrawal symptoms. A major criticism of methadone is the lack of a ceiling effect – higher doses lead to increased physiological impact. It is also heavily regulated and typically administered in clinics.
Buprenorphine, on the other hand, is a partial opioid agonist. This partial activation significantly reduces the risk of respiratory depression and allows for use outside of clinic settings.
Outside of pregnancy, buprenorphine is generally less effective in retaining patients in treatment. However, evidence in pregnant populations has been limited. The MOTHER trial (Maternal Opioid Treatment: Human Experimental Research) addressed this gap.
The study found higher discontinuation rates for buprenorphine compared to methadone (33% vs. 18%, respectively).
Variations in billing patterns and treatment gaps were also considered when defining treatment discontinuation.
Key Findings
Patients initiated on buprenorphine were:
- 41% more likely to discontinue treatment during pregnancy
- 37% more likely to discontinue treatment during the postpartum year
Compared to those on methadone.
During pregnancy, women typically receive consistent medical monitoring. After childbirth, that support often decreases, which may explain why 59% of buprenorphine patients and 47% of methadone patients discontinued treatment during the postpartum year.
Postpartum physiological changes, altered metabolism, chronic sleep deprivation, and increased stress may also impact medication effectiveness – especially for partial agonists like buprenorphine.
Despite higher retention with methadone, it is associated with higher rates of neonatal abstinence syndrome (NAS), including differences in infant weight and blood flow.
Personal Conclusion
Even with lower retention rates, I believe buprenorphine is the superior option due to its safety profile and lower toxicity. Increased postpartum medication coverage, better follow-up care, and stronger patient-provider connections could significantly improve outcomes.
Early Intervention and Neuroplasticity in Adolescence
This article highlights the importance of early intervention during adolescence, a period marked by heightened neuroplasticity in prefrontal brain circuits. Early treatment may lead to more resilient neural systems before disorders become chronic in adulthood.
Functional MRI activity may also serve as a biomarker for treatment readiness, with lower baseline levels indicating higher priority for intervention.
Interoceptive Exposure and Low-Weight Eating Disorders
This study examines low-weight eating disorders (LWED), finding that affected individuals exhibit resistance to food-cue extinction due to diminished anterior insula response.
Rather than fear, disgust appears to be the dominant barrier to weight gain. The anterior insula – central to interoception – integrates bodily signals. In LWED, food cues trigger disgust rather than appetite.
Interoceptive exposure therapy induces somatic sensations (such as fullness) in a safe environment, allowing the brain to relearn associations. Repeated exposure without negative outcomes increases appetite and insula activation.
This approach shows promise beyond eating disorders, offering a new direction beyond traditional cognitive-behavioral therapy.
Neuromodulation and Depression Treatment
While antidepressants and psychotherapy are effective for many individuals with major depressive disorder (MDD), a significant number continue to experience symptoms.
Transcranial direct current stimulation (tDCS) is a noninvasive neuromodulation technique that alters cortical excitability using low-intensity electrical currents. Though early results were promising, later studies produced mixed outcomes – possibly due to stimulation parameters.
Evidence suggests that multiple sessions spaced over time may significantly enhance therapeutic effects. tDCS remains a feasible and safe potential treatment for MDD.
Depression vs. Burnout
Depression and burnout are often confused but are not the same.
- Burnout is typically caused by chronic stress from responsibility and improves when the stressor is removed.
- Depression can occur with or without stress and includes persistent hopelessness, loss of interest, exhaustion, and suicidal thoughts.
Burnout is not a formal medical diagnosis but is widely recognized as a serious mental health struggle. In some cases, burnout can evolve into depression.